ArticleScientific reports2025
Quantitative proteomic analysis of the protective effect exerted by alliin on ox-LDL-injured HUVECs.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alliin Regulates Intracellular Cholesterol Metabolism Through the PCSK9/LDLR Axis in Ox-LDL-Induced HepG2 Cells: A Proteomics Study.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Natural organic sulfides are predominantly found in cruciferous and liliaceous plants. Among these compounds, alliin-an organic sulfide derived from garlic-has garnered significant attention from researchers due to its potential anti-atherosclerotic properties. However, studies specifically investigating the anti-atherosclerotic effects of alliin remain limited. This study aims to elucidate the protective effects of alliin on ox-LDL-injured human umbilical vein endothelial cells (HUVECs) and their underlying mechanisms. Initially, HUVECs were exposed to 80 mg/L oxidized low-density lipoprotein (ox-LDL) for 24 h to establish an ox-LDL injury model. Subsequently, the Cell Counting Kit-8 (CCK8) assay was utilized to assess the effect of alliin on the proliferation of ox-LDL-injured cells at 12, 24 and 48 h, and the levels of total cholesterol (TC) and free cholesterol (Fch) in the HUVECs were measured according to the instructions of TC and Fch kits. Next, quantitative proteomics was then adopted to analyze the differential protein expression in cell samples from the control group (Con), the ox-LDL injury model group (Mod), and the alliin treatment group (Alliin). Among the quantified proteins, a statistical t-test with P < 0.05 was used as a threshold for significance regarding a 1.5-fold change in differential expression. Finally, functional enrichment analysis of the differential proteins in the Alliin/Mod group was performed using Gene Ontology (GO) enrichment and KEGG pathway analysis. Additionally, Western blotting was used to validate the findings. The proteomic analysis identified 6173 identified proteins, of which 5162 were quantifiable. Differential protein analysis revealed that in the Alliin/Con comparison, there were a total of 108 up-regulated proteins and 116 down-regulated proteins; in the Alliin/Mod comparison there were a total of 33 up-regulated proteins and 17 down-regulated proteins; while in the Mod/Con comparison, there were a total of 106 up-regulated proteins and 147 down-regulated proteins. GO enrichment, KEGG pathway analyses and Western blotting verification demonstrated that alliin up-regulates the expression of Low-density lipoprotein receptor (LDLR) (P < 0.05) and apolipoprotein C (ApoC) (P < 0.05) while down-regulating the expression of apolipoprotein B (ApoB) (P < 0.05) to regulate the cholesterol metabolism pathway of the ox-LDL-injured HUVECs. Our findings highlight the importance of cholesterol metabolism in alliin treatment for atherosclerosis. Alliin exerts a protective effect in the ox-LDL-induced HUVEC injury model by modulating the expression of LDLR, ApoC, and ApoB within the cholesterol metabolism pathway. These findings indicate that alliin could potentially serve as a therapeutic agent for the prevention and treatment of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.